RxDoctor Payments Data

George Matthews, MD

Ophthalmology · Fort Worth, TXNPI 1922005396

Payments from drug & device makers

$2,881in general payments, 2019–2025

Across 14 payments — averaging $205.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eyepoint US, Inc.$2K
  • Novartis$239
  • Cardinal Health 108 LLC$117
  • Astellas Pharma US Inc$61
  • AbbVie$28
  • Genentech USA, Inc.$24
$1,565in research payments, 2019–2025

Across 8 payments — averaging $195.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$2K

What the payments were for

  • Travel & lodging$1,98669%
  • Food & beverage$89531%

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eyepoint US, Inc.5$2,411
Novartis3$239
Cardinal Health 108 LLC1$117
Astellas Pharma US Inc2$61
AbbVie2$28
Genentech USA, Inc.1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,881 in reported general payments places this provider in the 55th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$259,006
Medicare patients
279
Services billed
1,607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol38$4,376
Travoprost23$4,265
AlrexLoteprednol Etabonate14$3,917
CombiganBrimonidine Tartrate/Timolol13$3,159
Latanoprost423$2,718
SimbrinzaBrinzolamide/Brimonidine Tart11$2,342
Prednisolone Acetate77$1,999
Brimonidine Tartrate62$911
Timolol Maleate55$855
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat77$823
Betaxolol Hcl13$820
Dorzolamide Hcl25$361
Gentamicin Sulfate23$183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan$28$3,15913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →